Data from: Analysis of the cerebrospinal fluid proteome in Alzheimer's disease
Data files
Mar 14, 2017 version files 9.16 GB
-
AD1_1.RAW
244.05 MB
-
AD1_2.RAW
247.17 MB
-
AD10_1.RAW
188.56 MB
-
AD10_2.RAW
215.40 MB
-
AD2_1.RAW
210.56 MB
-
AD2_2.RAW
226.16 MB
-
AD3_1.RAW
228.95 MB
-
AD3_2.RAW
232.51 MB
-
AD4_1.RAW
237.54 MB
-
AD4_2.RAW
245.41 MB
-
AD5_1.RAW
246.53 MB
-
AD5_2.RAW
241.03 MB
-
AD6_1.RAW
218.33 MB
-
AD6_2.RAW
244.83 MB
-
AD7_1.RAW
235.42 MB
-
AD7_2.RAW
238.34 MB
-
AD8_1.RAW
236.58 MB
-
AD8_2.RAW
243.54 MB
-
AD9_1.RAW
187.77 MB
-
AD9_2.RAW
189.16 MB
-
C1_1.RAW
233.64 MB
-
C1_2.RAW
244.39 MB
-
C10_1.RAW
231.50 MB
-
C10_2.RAW
238.86 MB
-
C2_1.RAW
221.50 MB
-
C2_2.RAW
231.38 MB
-
C3_1.RAW
232.01 MB
-
C3_2.RAW
238.80 MB
-
C4_1.RAW
216.32 MB
-
C4_2.RAW
236.26 MB
-
C5_1.RAW
225.46 MB
-
C5_2.RAW
228.02 MB
-
C6_1.RAW
236.72 MB
-
C6_2.RAW
247.60 MB
-
C7_1.RAW
201.55 MB
-
C7_2.RAW
218.34 MB
-
C8_1.RAW
222.49 MB
-
C8_2.RAW
228.10 MB
-
C9_1.RAW
220.56 MB
-
C9_2.RAW
247.24 MB
Abstract
Alzheimer’s disease is a neurodegenerative disorder accounting for more than 50% of cases of dementia. Diagnosis of Alzheimer’s disease relies on cognitive tests and analysis of amyloid beta, protein tau, and hyperphosphorylated tau in cerebrospinal fluid. Although these markers provide relatively high sensitivity and specificity for early disease detection, they are not suitable for monitor of disease progression. In the present study, we used label-free shotgun mass spectrometry to analyse the cerebrospinal fluid proteome of Alzheimer’s disease patients and non-demented controls to identify potential biomarkers for Alzheimer’s disease. We processed the data using five programs (DecyderMS, Maxquant, OpenMS, PEAKS, and Sieve) and compared their results by means of reproducibility and peptide identification, including three different normalization methods. After depletion of high abundant proteins we found that Alzheimer’s disease patients had lower fraction of low-abundance proteins in cerebrospinal fluid compared to healthy controls (p<0.05). Consequently, global normalization was found to be less accurate compared to using spiked-in chicken ovalbumin for normalization. In addition, we determined that Sieve and OpenMS resulted in the highest reproducibility and PEAKS was the programs with the highest identification performance. Finally, we successfully verified significantly lower levels (p<0.05) of eight proteins (A2GL, APOM, C1QB, C1QC, C1S, FBLN3, PTPRZ, and SEZ6) in Alzheimer’s disease compared to controls using an antibody-based detection method. These proteins are involved in different biological roles spanning from cell adhesion and migration, to regulation of the synapse and the immune system.